1. Home
  2. CYTK vs ALKS Comparison

CYTK vs ALKS Comparison

Compare CYTK & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • ALKS
  • Stock Information
  • Founded
  • CYTK 1997
  • ALKS 1987
  • Country
  • CYTK United States
  • ALKS Ireland
  • Employees
  • CYTK N/A
  • ALKS N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • ALKS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYTK Health Care
  • ALKS Health Care
  • Exchange
  • CYTK Nasdaq
  • ALKS Nasdaq
  • Market Cap
  • CYTK 5.6B
  • ALKS 5.1B
  • IPO Year
  • CYTK 2004
  • ALKS 1991
  • Fundamental
  • Price
  • CYTK $32.43
  • ALKS $29.09
  • Analyst Decision
  • CYTK Buy
  • ALKS Buy
  • Analyst Count
  • CYTK 14
  • ALKS 12
  • Target Price
  • CYTK $70.92
  • ALKS $40.00
  • AVG Volume (30 Days)
  • CYTK 1.3M
  • ALKS 1.6M
  • Earning Date
  • CYTK 08-07-2025
  • ALKS 07-23-2025
  • Dividend Yield
  • CYTK N/A
  • ALKS N/A
  • EPS Growth
  • CYTK N/A
  • ALKS N/A
  • EPS
  • CYTK N/A
  • ALKS 2.09
  • Revenue
  • CYTK $19,218,000.00
  • ALKS $1,513,770,000.00
  • Revenue This Year
  • CYTK $18.02
  • ALKS N/A
  • Revenue Next Year
  • CYTK $737.32
  • ALKS $4.25
  • P/E Ratio
  • CYTK N/A
  • ALKS $13.92
  • Revenue Growth
  • CYTK 412.21
  • ALKS N/A
  • 52 Week Low
  • CYTK $29.31
  • ALKS $22.90
  • 52 Week High
  • CYTK $61.38
  • ALKS $36.45
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 46.32
  • ALKS 38.82
  • Support Level
  • CYTK $32.02
  • ALKS $29.26
  • Resistance Level
  • CYTK $34.72
  • ALKS $30.52
  • Average True Range (ATR)
  • CYTK 1.30
  • ALKS 0.78
  • MACD
  • CYTK 0.26
  • ALKS -0.24
  • Stochastic Oscillator
  • CYTK 45.08
  • ALKS 4.96

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Share on Social Networks: